Relationship between medical specialty (medical oncology vs. others) and percentage of highly important response scores (>3) estimated for each statement through logistic regression analyses
| Statement | OR | 95% CL |
|---|---|---|
| S1. No mortality effect. | 0.89 | 0.40–1.94 |
| S5. Risk models are difficult | 1.00 | 0.43–2.27 |
| S8. Drugs have no commercial interest | 1.42 | 0.58–3.43 |
| S10. AIs better than SERMs | 1.49 | 0.60–3.68 |
| S4. Unclear who is the appropriate physician | 1.56 | 0.69–3.49 |
| S9. Off label in EU | 1.57 | 0.68–3.62 |
| S6. Lack of medical knowledge | 1.72 | 0.72–4.12 |
| S7. Prevention of curable cancers | 1.74 | 0.73–4.12 |
| S2 Drugs have adverse events | 1.84 | 0.79–4.24 |
| S3. Lack of reliable biomarkers | 2.42 | 0.93–6.25 |
OR, odds ratio adjusted for gender, age at survey, and life expectancy at birth; 95% CL, confidence interval.